bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models
Authors: Burke Patrick J. , Hamilton Joseph Z. , Pires Thomas A. , Lai Holden W.H. , Leiske Christopher I. , Emmerton Kim K. , Waight Andrew B. , Senter Peter D. , Lyon Robert P. , Jeffrey Scott C.
Published: April 2023

rat tolerability
Supplementary Table 1 from ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Authors: Ward George A. , Lewis Edward J. , Ahn Jong Sook , Johnson Christopher N. , Lyons John F. , Martins Vanessa , Munck Joanne M. , Rich Sharna J. , Smyth Tomoko , Thompson Neil T. , Williams Pamela A. , Wilsher Nicola E. , Wallis Nicola G. , Chessari Gianni
Published: April 2023

Comparison of XIAP activity, cIAP1 activity and selectivity of clinical IAP antagonists
Table S1 from Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Authors: Wu Zhihao , Guo Hong-Fen , Xu Hong , Cheung Nai-Kong V.
Published: April 2023

This table provides the MFI values of different cell lines using huA33-BsAb
Table S1 from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Authors: Garcia Patrick L. , Miller Aubrey L. , Gamblin Tracy L. , Council Leona N. , Christein John D. , Arnoletti J. Pablo , Heslin Marty J. , Reddy Sushanth , Richardson Joseph H. , Cui Xiangqin , van Waardenburg Robert C.A.M. , Bradner James E. , Yang Eddy S. , Yoon Karina J.
Published: April 2023

Time course of increase in tumor volume in mice treated with vehicle (VC) or JQ1.
Figure S1 from Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer
Authors: Sunakawa Yu , Mogushi Kaoru , Lenz Heinz-Josef , Zhang Wu , Tsuji Akihito , Takahashi Takehiro , Denda Tadamichi , Shimada Ken , Kochi Mitsugu , Nakamura Masato , Kotaka Masahito , Segawa Yoshihiko , Tanioka Hiroaki , Negoro Yuji , Moran Miriana , Astrow Stephanie H. , Hsiang Jack , Stephens Craig , Fujii Masashi , Ichikawa Wataru
Published: April 2023

Consort flow diagram of the study
Figure S4 from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Authors: Garcia Patrick L. , Miller Aubrey L. , Gamblin Tracy L. , Council Leona N. , Christein John D. , Arnoletti J. Pablo , Heslin Marty J. , Reddy Sushanth , Richardson Joseph H. , Cui Xiangqin , van Waardenburg Robert C.A.M. , Bradner James E. , Yang Eddy S. , Yoon Karina J.
Published: April 2023

Immunoblot analysis showing that JQ1 downregulates TEK, Chk1, MSH2 and LCK expression in CCA2 tumors, but not in CCA1 tumors.
Figure S1 from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Authors: Garcia Patrick L. , Miller Aubrey L. , Gamblin Tracy L. , Council Leona N. , Christein John D. , Arnoletti J. Pablo , Heslin Marty J. , Reddy Sushanth , Richardson Joseph H. , Cui Xiangqin , van Waardenburg Robert C.A.M. , Bradner James E. , Yang Eddy S. , Yoon Karina J.
Published: April 2023

Patient-derived xenograft (PDX) models of cholangiocarcinoma (CCA): tumor growth and histology.
Supplementary Methods from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
Authors: Cho Song , Zammarchi Francesca , Williams David G. , Havenith Carin E.G. , Monks Noel R. , Tyrer Peter , D'Hooge Francois , Fleming Ryan , Vashisht Kapil , Dimasi Nazzareno , Bertelli Francois , Corbett Simon , Adams Lauren , Reinert Halla W. , Dissanayake Sandamali , Britten Charles E. , King Wanda , Dacosta Karma , Tammali Ravinder , Schifferli Kevin , Strout Patrick , Korade Martin , Masson Hinrichs Mary Jane , Chivers Simon , Corey Eva , Liu He , Kim Sae , Bander Neil H. , Howard Philip W. , Hartley John A. , Coats Steve , Tice David A. , Herbst Ronald , van Berkel Patrick H.
Published: April 2023

Supplementary Methods
Supplementary Table S1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Supplementary Table S1 shows the cell surface density (expressed as number of receptors per cell) for CD19, CD47, CD20 on different subpopulations in human whole blood
Figure S1 from Death by HDAC Inhibition in Synovial Sarcoma Cells
Authors: Laporte Aimée N. , Poulin Neal M. , Barrott Jared J. , Wang Xiu Qing , Lorzadeh Alireza , Vander Werff Ryan , Jones Kevin B. , Underhill T. Michael , Nielsen Torsten O.
Published: April 2023

Supplementary Figure S1
Supplementary Figure 2 from RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE
Authors: Suthe Sreedhar Reddy , Yao Hang-Ping , Weng Tian-Hao , Hu Chen-Yu , Feng Liang , Wu Zhi-Gang , Wang Ming-Hai
Published: April 2023

Fig. S2 is about the cytotoxic effect of Zt/g4-MMAE on a panel of TNBC cell lines
Supplementary Table 3 from Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies
Authors: Shatsky Rebecca , Parker Barbara A. , Bui Nam Q. , Helsten Teresa , Schwab Richard B. , Boles Sarah G , Kurzrock Razelle
Published: April 2023

This table shows the 70 gene panel (ctDNA).
Supplementary Figures S1-S3 from Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy
Authors: Lepikhova Tatiana , Karhemo Piia-Riitta , Louhimo Riku , Yadav Bhagwan , Murumägi Astrid , Kulesskiy Evgeny , Kivento Mikko , Sihto Harri , Grénman Reidar , Syrjänen Stina M. , Kallioniemi Olli , Aittokallio Tero , Wennerberg Krister , Joensuu Heikki , Monni Outi
Published: April 2023

Figure S1. Heat map of drug responses of 220 compounds across 45 HPV negative cell lines. Figure S2. DSS scores and grouping of the used drugs based on their functional categories. Figure S3. An effect of transient knock-down of RAB25 and FAM83H to the cellular response of EGFR inhibitors afatinib and erlotinib.
Supplementary Methods from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
Authors: Visintin Alberto , Knowlton Kelly , Tyminski Edyta , Lin Chi-Iou , Zheng Xiang , Marquette Kimberly , Jain Sadhana , Tchistiakova Lioudmila , Li Dan , O'Donnell Christopher J. , Maderna Andreas , Cao Xianjun , Dunn Robert , Snyder William B. , Abraham Anson K. , Leal Mauricio , Shetty Shoba , Barry Anthony , Zawel Leigh , Coyle Anthony J. , Dvorak Harold F. , Jaminet Shou-Ching
Published: April 2023

Supplementary Methods
Figure S6 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation
Authors: Singh Pankaj K. , Deorukhkar Amit A. , Venkatesulu Bhanu P. , Li Xiaolin , Tailor Ramesh , Bomalaski John S. , Krishnan Sunil
Published: April 2023

SiRNA
Supplementary Figure S1 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
Authors: Buondonno Ilaria , Gazzano Elena , Jean Sae Rin , Audrito Valentina , Kopecka Joanna , Fanelli Marilù , Salaroglio Iris C. , Costamagna Costanzo , Roato Ilaria , Mungo Eleonora , Hattinger Claudia M. , Deaglio Silvia , Kelley Shana O. , Serra Massimo , Riganti Chiara
Published: April 2023

Chemical structure of mitochondria-targeted doxorubicin
Supplementary Data from Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models
Authors: Nguyen Thinh H. , Koneru Balakrishna , Wei Sung-Jen , Chen Wan Hsi , Makena Monish Ram , Urias Eduardo , Kang Min H. , Reynolds C. Patrick
Published: April 2023

Supplementary Data and Tables
Figure S3 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Authors: Hao Huai-Xiang , Wang Hongyun , Liu Chen , Kovats Steven , Velazquez Roberto , Lu Hengyu , Pant Bhavesh , Shirley Matthew , Meyer Matthew J. , Pu Minying , Lim Joanne , Fleming Michael , Alexander LeighAnn , Farsidjani Ali , LaMarche Matthew J. , Moody Susan , Silver Serena J. , Caponigro Giordano , Stuart Darrin D. , Abrams Tinya J. , Hammerman Peter S. , Williams Juliet , Engelman Jeffrey A. , Goldoni Silvia , Mohseni Morvarid
Published: April 2023

(A) In vivo primary human colorectal xenograft model HCOX4087 treated with trametinib (0.3 mg/kg QD), SHP099 (100 mg/kg QD), and a pan-RTK inhibitor, Dovitinib (100 mg/kg QD). (B-C) In vivo efficacy of selective VEGFR2 inhibitor, BFH772 (3 mg/kg QD) in MIA PaCA-2 and T3M-4 cells implanted subcutaneously. Data plotted are tumor volume means {plus minus} s.e.m (T3M-4, n=8. MIA PaCA-2, n=7) (D) Evaluation of SHP099 in firefly- luciferase labeled MIA PaCa-2 pancreatic cells implanted surgically into the mouse pancreas. Data plotted are mean bioluminescent signal (BLI) {plus minus} s.e.m (n=6). (E-F) Immunoblot of SHP2 and soft agar assay with MIA Paca-2 cells with Dox-inducible shRNA targeting SHP2 or control non-targeting shRNA after Dox treatment. (G) In vivo SHP2 expression levels evaluated by Western blot and levels of MAPK pathway suppression by DUSP6, 3 hours after the last dose of SHP099 from MIA PaCa-2 tumors in Fig. 4F (n=3).
Supplementary Tables S1-S6 and Figures S1-S4 from Transgelin 2 Promotes Paclitaxel Resistance, Migration, and Invasion of Breast Cancer by Directly Interacting with PTEN and Activating PI3K/Akt/GSK-3β Pathway
Authors: Liu Leichao , Meng Ti , Zheng Xiaowei , Liu Yang , Hao Ruifang , Yan Yan , Chen Siying , You Haisheng , Xing Jianfeng , Dong Yalin
Published: April 2023

Table S1. Primer lists of qPCR; Table S2. Correlation of Transgelin 2 expression with clinicopathological parameters in breast cancer; Table S3ï¼ŽCorrelation of Transgelin 2 mRNA expression with clinicopathological features in breast cancer by multivariate logistic regression analysis; Table S4. The identification of the peak; Table S5. The annotation of the peak; Table S6. The effects of MK-2206 on IC50 value of paclitaxel in MCF-7/PTX cells; Figure S1. Differential expression of Transgelin 2 mRNA of different clinicopathological characteristics; Figure S2. Transgelin 2 expression in breast cancer cell lines; Figure S3. Transgelin 2 has no effect on the stability of the PTEN protein; Figure S4. Schematic depiction of the mechanisms underlying Transgelin 2-mediated paclitaxel resistance, migration and invasion of breast cancer by directly interacting with PTEN and activating PI3K/Akt/GSK-3Î² pathway.
Figure S7 from Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer
Authors: Shin Dong Hoon , Jo Jeong Yeon , Han Ji-Youn
Published: April 2023

The lungs of nude mice (8 weeks) were infected with adenovirus expressing E.V. or Flag-S-N gene (3x1011 PFU) through intratracheal injection once per two weeks for 2 months and then checked lung morphology and confirm plasmid infection through Western blots.
Supplemental Table S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Authors: Whalen Kerry A. , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Alargova Rossitza , Au Yeung Tsun P. , Bazinet Patrick , Brockman Adam , DuPont Michelle M. , Oller Haley , Gifford James , Lemelin Charles-Andre , Lim Soo Patrick , Perino Samantha , Moreau Benoît , Sharma Gitanjali , Shinde Rajesh , Sweryda-Krawiec Beata , Bilodeau Mark T. , Wooster Richard
Published: April 2023

Immunohistochemical Analysis of SSTR2 Expression in 35 Small Cell Lung Cancer Patient Samples
Supplementary Video S1B from Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition
Authors: Scott Gary K. , Yau Christina , Becker Beatrice C. , Khateeb Sana , Mahoney Sophia , Jensen Martin Borch , Hann Byron , Cowen Bryan J. , Pegan Scott D. , Benz Christopher C.
Published: April 2023

To demonstrate that the oral N-PPG treatment (treated flies in Suppl. Fig 3B panel A) phenocopies the Sluggish-A phenotype of SlgA null mutant flies as previously described (18), geotaxis of untreated SlgA mutant flies is video illustrated (right tube) and compared to that of untreated wildtype flies (left tube).
Supplemental Figure 5 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Authors: Kietzman William B. , Graham Garrett T. , Ory Virginie , Sharif Ghada M. , Kushner Max H. , Gallanis Gregory T. , Kallakury Bhaskar , Wellstein Anton , Riegel Anna T.
Published: April 2023

MUC16 and Tumor cell Death
Supplementary Figure 4 - Niraparib induces growth arrest in SJG2 and SF188 cells. from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma
Authors: Chornenkyy Yevgen , Agnihotri Sameer , Yu Man , Buczkowicz Pawel , Rakopoulos Patricia , Golbourn Brian , Garzia Livia , Siddaway Robert , Leung Stephie , Rutka James T. , Taylor Michael D. , Dirks Peter B. , Hawkins Cynthia
Published: April 2023

A, B, MTT viability relative absorbance values of SJG2 and SF188 after being treated with an indicated concentration of Niraparib for 72h. C, Western blot for cleaved PARP1 in SJG2 and SF188 after being treated with an indicated concentration of Niraparib for 72h. D, E, Propidium Iodide DNA staining analysis in SJG2, SF188 cells, respectively, after a 72h incubation with an indicated concentration of Niraparib. *, ***, **** Denotes significance of p<0.05, p<0.001, p<0.0001, respectively. Error bars represent SEM.
Supplementary Figure 3B and C from Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
Authors: Kang Chan Woo , Jang Kang Won , Sohn Jinyoung , Kim Sung-Moo , Pyo Kyoung-Ho , Kim Hwan , Yun Mi Ran , Kang Han Na , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Paik Soonmyung , Kim Dae Joon , Kim Joo Hang , Cho Byoung Chul
Published: April 2023

Supplementary Figure 3B and C. Inhibition of FAK activity in LC-2/ad cells and LC-2/ad DR cells B, Western blot analysis of indicated markers in LC-2/ad and LC-2/ad DR cells after treated with 1mM of dovitinib (DO), dasatinib (DA), saracatinib (SA), or PF562,271 (PF) for 4hr. C, Western blot analysis of indicated markers in LC-/2ad and LC-2/ad DR cells after treated with indicated dose of dovitinib (DO) for 4hr.
Supplementary Table 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Authors: Lu Hengyu , Liu Chen , Velazquez Roberto , Wang Hongyun , Dunkl Lukas Manuel , Kazic-Legueux Malika , Haberkorn Anne , Billy Eric , Manchado Eusebio , Brachmann Saskia M. , Moody Susan E. , Engelman Jeffrey A. , Hammerman Peter S. , Caponigro Giordano , Mohseni Morvarid , Hao Huai-Xiang
Published: April 2023

mRNA levels (TPM, transcripts per million reads in RNAseq) of SHP2, RTKs, and their ligands in all cell lines tested.
Supplementary Table 1 from The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells
Authors: Bergès Raphaël , Tchoghandjian Aurélie , Honoré Stéphane , Estève Marie-Anne , Figarella-Branger Dominique , Bachmann Felix , Lane Heidi A. , Braguer Diane
Published: April 2023

Sequences of primers used in RT-qPCR
Supplementary Table 4 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Authors: Couëtoux du Tertre Mathilde , Marques Maud , Tremblay Lise , Bouchard Nicole , Diaconescu Razvan , Blais Normand , Couture Christian , Pelsser Vincent , Wang Hangjun , Higenell Valerie , Izzi Luisa , Gambaro Karen , Hoffert Cyrla , Srivastava Archana , Spatz Alan , Rousseau Caroline , McNamara Suzan , Cohen Victor , Batist Gerald , Agulnik Jason
Published: April 2023

Regions associated with crizotinib-related PFS
Supplemental Figure 4 from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

APE1/Ref-1 interactions with HIF1α and STAT3 are stimulated by hypoxia in Cancer-Associated Fibroblast (CAF) cells
Supplementary Table S1 from The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo
Authors: Kim Julie , Wang Chao , de Sabando Ainara Ruiz , Cole Hannah L. , Huang Timothy J. , Yang Jie , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

Statistical analysis of cell proliferation and MTS assays.
Table S2 from Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Authors: Park Pyoung Hwa , Yamamoto Tomomi M. , Li Hua , Alcivar Allen L. , Xia Bing , Wang Yifan , Bernhardy Andrea J. , Turner Kristen M. , Kossenkov Andrew V. , Watson Zachary L. , Behbakht Kian , Casadei Silvia , Swisher Elizabeth M. , Mischel Paul S. , Johnson Neil , Bitler Benjamin G.
Published: April 2023

Single nucleotide polymorphisms (SNP) in Capan1 olaparib resistant cells
Supplemental Figure 6 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Authors: Flynn Michael J. , Zammarchi Francesca , Tyrer Peter C. , Akarca Ayse U. , Janghra Narinder , Britten Charles E. , Havenith Carin E.G. , Levy Jean-Noel , Tiberghien Arnaud , Masterson Luke A. , Barry Conor , D'Hooge Francois , Marafioti Teresa , Parren Paul W.H.I. , Williams David G. , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

In vivo efficacy in Ramos disseminated model. Kaplan Meier survival plots of disseminated CD25-negative Ramos model
Supplemental Figure 5 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Authors: Flynn Michael J. , Zammarchi Francesca , Tyrer Peter C. , Akarca Ayse U. , Janghra Narinder , Britten Charles E. , Havenith Carin E.G. , Levy Jean-Noel , Tiberghien Arnaud , Masterson Luke A. , Barry Conor , D'Hooge Francois , Marafioti Teresa , Parren Paul W.H.I. , Williams David G. , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

In vivo efficacy in Karpas disseminated models. Kaplan Meier survival plots of disseminated Karpas 299 models
Supplementary Figures S1-S6 from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
Authors: Geretti Elena , Leonard Shannon Curtis , Dumont Nancy , Lee Helen , Zheng Jinzi , De Souza Raquel , Gaddy Daniel F. , Espelin Christopher W. , Jaffray David A. , Moyo Victor , Nielsen Ulrik B. , Wickham Thomas J. , Hendriks Bart S.
Published: April 2023

Supplementary Figures S1-S6. Supplementary Fig. S1. The effect of cyclophosphamide on liposome delivery is dose dependent, requires a predose rather than a co-injection, and is not mediated by changes in blood clearance. Supplementary Fig. S2. Cyclophosphamide induces DNA-damage and tumor cell apoptosis. Supplementary Fig. S3. Effects of cyclophosphamide, ifosfamide, paclitaxel and eribulin on HER2-tPLD delivery, stromal cell density, total cell density, and interstitial space area. Supplementary Fig. S4. Pretreatment of tumors with cyclophosphamide significantly enhances nuclear delivery of doxorubicin following HER2-tPLD injection. Supplementary Fig. S5. Pretreatment of tumors with cyclophosphamide enhances the delivery of HER2-tPLD in multiple tumor models. Supplementary Fig. S6. The combination of a cyclophosphamide predose with HER2-tPLD results in synergistic anti-tumor activity.
Supplementary Figures 1-5 from In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma
Authors: Sanchez Ileine M. , Purwin Timothy J. , Chervoneva Inna , Erkes Dan A. , Nguyen Mai Q. , Davies Michael A. , Nathanson Katherine L. , Kemper Kristel , Peeper Daniel S. , Aplin Andrew E.
Published: April 2023

Supplemental Fig. 1. Combination-resistant and combination tolerant tumors re-activated ERK1/2 before progression. Supplemental Fig. 2. Combination-resistant tumor-derived cell lines progressed through cell cycle during combo treatment. Supplemental Fig 3. CRTs harbored tandem duplication of kinase domain but remained sensitive to ERK1/2 inhibition. Supplemental Fig. 4. Both intermittently and continuously treated tumors reactivated of ERK1/2 in vitro. Supplemental Fig. 5. Pathway analysis identified Plk11 as selective driver of resistance in CRTs.
Supplementary Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
Authors: Capdevila Jaume , Matos Ignacio , Mancuso Francesco M. , Iglesias Carmela , Nuciforo Paolo , Zafon Carles , Palmer Hector G. , Ogbah Zighereda , Muiños Laura , Hernando Jorge , Villacampa Guillermo , Peña Carol E. , Tabernero Josep , Brose Marcia S. , Schlumberger Martin , Vivancos Ana
Published: April 2023

Table 1: samples included in the RNAseq analysis Figure 1: consort flow diagram Table 2: Comparison of patients' characteristics of the subset of patients included in the RNA-seq analysis and patients recruited in the DECISION study Figure 2: Progression-free survival of the subgroup of patients included in the RNA-seq analysis. Table 3: Pathways_GO_analysis Figure 3: Kaplan-Meyer curves of the three RNA expression groups regarding treatment group in DECISION trial. Figure 4: A,B,C: PFS in papillary, follicular and poorly differentiated histologies, respectively; D,E,F: OS in papillary, follicular and poorly differentiated histologies, respectively Figure 5: Overall survival (OS) analysis based on RNA expression profile from TCGA data of papillary thyroid cancer (Cell, 2014) Figure 6: Analyses based on 121 angiogenesisrelated genes
Supplementary Figure 3 from Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Authors: Fishel Melissa L. , Xia Hanyu , McGeown Jack , McIlwain David W. , Elbanna May , Craft Ariel A. , Kaimakliotis Hristos Z. , Sandusky George E. , Zhang Chi , Pili Roberto , Kelley Mark R. , Jerde Travis J.
Published: April 2023

Confirmation of cell death induction by caspase activity assay and PARP cleavage. Representative images for caspase activity via red fluorescence [A] for the data calculated and shown in Figure 2, each with matching brightfield images. Representative examples for T24 and UC3 cells are shown form cells treated with the growth-inhibitor EC50 concentrations for each drug, in each cell line. PARP cleavage was used to confirm the induction of apoptotic mechanisms by western blotting for cleaved PARP1 [B], with representative cell experiments in which UC3 cells were treated with EC50 and EC90 concentrations of each drug.
Supplementary Table S1 from MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling
Authors: Qu Jia-Quan , Yi Hong-Mei , Ye Xu , Zhu Jin-Feng , Yi Hong , Li Li-Na , Xiao Ta , Yuan Li , Li Jiao-Yang , Wang Yuan-Yuan , Feng Juan , He Qiu-Yan , Lu Shan-Shan , Xiao Zhi-Qiang
Published: April 2023

The clinicopathological parameters of 111 patients with nasopharygeal carcinoma
Supplementary Table S1 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Authors: Burova Elena , Hermann Aynur , Dai Jie , Ullman Erica , Halasz Gabor , Potocky Terra , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Pei Jerry , Rafique Ashique , Poueymirou William , Martin Joel , MacDonald Douglas , Olson William C. , Murphy Andrew , Ioffe Ella , Thurston Gavin , Mohrs Markus
Published: April 2023

Supplementary Table S1 shows results of treatment with cemiplimab and REGN3767 in in vivo tumor model
Supplementary Materials and Methods; Supplementary Table S1; Supplementary Figures S1-S5 from Improvement of Stability and Efficacy of C16Y Therapeutic Peptide via Molecular Self-Assembly into Tumor-Responsive Nanoformulation
Authors: Ding Yanping , Ji Tianjiao , Zhao Ying , Zhang Yinlong , Zhao Xiaozheng , Zhao Ruifang , Lang Jiayan , Zhao Xiao , Shi Jian , Sukumar Saraswati , Nie Guangjun
Published: April 2023

Supplementary Materials and Methods; Supplementary Table S1; Supplementary Figures S1-S5. Supplementary materials and methods shows detailed materials and methods of evaluation of the drug loading and release profiles of DEAP-C16Y-Dox. Supplementary Table S1 shows encapsulation and loading efficiency of Dox in DEAP-C16Y-Dox or DEAP-HSAF-Dox. Supplementary Figure S1 shows characterization of the DEAP-C16Y self-assembling nanoprobe. Supplementary Figure S2 shows DEAP-HSAF nanostructure and effects of DEAP-C16Y on endothelial cells and tumor cells. Supplementary Figure S3 shows biodistribution and antitumor efficacy of DEAP-C16Y nanostructures. Supplementary Figure S4 shows the potential toxicity of DEAP-C16Y nanostructures. Supplementary Figure S5 shows combination therapy of DEAP-C16Y and Dox.
Supplementary Figure S5 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Authors: Burova Elena , Hermann Aynur , Dai Jie , Ullman Erica , Halasz Gabor , Potocky Terra , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Pei Jerry , Rafique Ashique , Poueymirou William , Martin Joel , MacDonald Douglas , Olson William C. , Murphy Andrew , Ioffe Ella , Thurston Gavin , Mohrs Markus
Published: April 2023

Supplementary Figure S5 shows expression of human PD-1 and human LAG-3 in PD-1xLAG-3 mice
Figure S1-S4 and Table S1-S2 from KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations
Authors: Liu Xiaoni , Zhang Shang-Min , McGeary Meaghan K. , Krykbaeva Irina , Lai Ling , Jansen Daniel J. , Kales Stephen C. , Simeonov Anton , Hall Matthew D. , Kelly Daniel P. , Bosenberg Marcus W. , Yan Qin
Published: April 2023

Figure S1. Responses of different YUMM cell lines to BRAFi treatment; Figure S2. Inhibition of KDM5 family members by shRNA knockdown and pan-KDM5 inhibitors; Figure S3. Subpopulation composition in tumors of different volumes; Figure S4. In vivo BRAFi/MEKi treatment of grafted YUMM1.7 tumors induced Kdm5b expression and increased CD34- subpopulation; Table S1. List of RT-qPCR primers; Table S2. Subpopulation composition of different YUMM cell lines.
Supplementary Tables 1-3 and Supplementary Figures 1-4 from Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Authors: Piperno-Neumann Sophie , Larkin James , Carvajal Richard D. , Luke Jason J. , Schwartz Gary K. , Hodi F. Stephen , Sablin Marie-Paule , Shoushtari Alexander N. , Szpakowski Sebastian , Chowdhury Niladri Roy , Brannon A. Rose , Ramkumar Thiruvamoor , de Koning Leanne , Derti Adnan , Emery Caroline , Yerramilli-Rao Padmaja , Kapiteijn Ellen
Published: April 2023

Supplementary Table 1 shows the adverse events suspected to be study drug-related. Supplementary Table 2 shows the sequencing data availability by treatment group. Supplementary Table 3 shows the observed correlations between selected mutations/alterations. Supplementary Figure 1 shows the time on study for each patient. Supplementary Figure 2 shows the gene alterations ordered by chromosome and PFS. Supplementary Figure 3 shows gene alterations ordered by chromosome and percentage change from baseline. Supplementary Figure 4 shows Kaplan-Meier plot of PFS for patients with or without a GNAQ mutation.
Supplementary Legends and Figure S1-S8 from Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer
Authors: Wang Caiyun , Wang Tao , Lv Dacheng , Li Ling , Yue Jinnan , Chen Hong-Zhuan , Xu Lu
Published: April 2023

Supplementary Legends and Figures S1-S8 show ITGB3 expression and function in acquired resistance
Supplementary Figure 1 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
Authors: Rosas-Plaza Ximena , de Vries Gerda , Meersma Gert Jan , Suurmeijer Albert J.H. , Gietema Jourik A. , van Vugt Marcel A.T.M. , de Jong Steven
Published: April 2023

Cisplatin sensitivity in TC cells and RTK validation on western blot
Supplementary Figure S3 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
Authors: Lopez Salvatore , Cocco Emiliano , Black Jonathan , Bellone Stefania , Bonazzoli Elena , Predolini Federica , Ferrari Francesca , Schwab Carlton L. , English Diana P. , Ratner Elena , Silasi Dan-Arin , Azodi Masoud , Schwartz Peter E. , Terranova Corrado , Angioli Roberto , Santin Alessandro D.
Published: April 2023

Cell proliferation assay of USPC-ARK-1 cells exposed for 2 weeks as described in the method section to taselisib (A, upper panel) or neratinib (B, lower panel) and treated thereafter with neratinib, taselisib and the combination of both agents at the indicated concentration for 72 hrs. Cell viability was analyzed by flow cytometry and was normalized to the mean of the control group receiving no drug, so that all data were expressed as a proportion of the control. Data are expressed as mean {plus minus} SEM from two independent experiments. As shown in the upper panel, taselisib-resistant USPC-ARK-1 cells while resistant to the PI3K inihibitor remain sensitive to single agent neratinib and highly responsive to the drug combination. In contrast, as shown in the lower panel, in vitro-neratinib-resistant cells demonstrate resistance to both single agent neratinib and taselisib but remain highly sensitive to the exposure to the drug combination.
Supplementary Figure 2 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Authors: Chlenski Alexandre , Park Chanyoung , Dobratic Marija , Salwen Helen R. , Budke Brian , Park Jae-Hyun , Miller Ryan , Applebaum Mark A. , Wilkinson Emma , Nakamura Yusuke , Connell Philip P. , Cohn Susan L.
Published: April 2023

MELK and EZH2 RNA expression
Supplementary Method from Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma
Authors: Singh Alok R. , Joshi Shweta , Burgoyne Adam M. , Sicklick Jason K. , Ikeda Sadakatsu , Kono Yuko , Garlich Joseph R. , Morales Guillermo A. , Durden Donald L.
Published: April 2023

Contain description of Supplementary methods and legends to supplementary figures and tables
Fig. S2 from Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma
Authors: Singh Alok R. , Joshi Shweta , Burgoyne Adam M. , Sicklick Jason K. , Ikeda Sadakatsu , Kono Yuko , Garlich Joseph R. , Morales Guillermo A. , Durden Donald L.
Published: April 2023

SF1126 and Sorafenib inhibit cell cycle progression by inducing apoptosis
Supplementary Figure 2 from Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Authors: Flem-Karlsen Karine , McFadden Erin , Omar Nasrin , Haugen Mads H. , Øy Geir Frode , Ryder Truls , Gullestad Hans Petter , Hermann Robert , Mælandsmo Gunhild Mari , Flørenes Vivi Ann
Published: April 2023

Supplementary Figure 2 shows animal weight throughout the treatment period.
Supplememntary Table 3 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
Authors: Restelli Valentina , Lupi Monica , Chilà Rosaria , Vagni Micaela , Tarantelli Chiara , Spriano Filippo , Gaudio Eugenio , Bertoni Francesco , Damia Giovanna , Carrassa Laura
Published: April 2023

GSEA of transcripts upregulated in cells with low sensitivity (non-responders) to AZD6738.
Figure S4 from Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Authors: Feng Tianshu , Golji Javad , Li Ailing , Zhang Xiamei , Ruddy David A. , Rakiec Daniel P. , Geyer Felipe C. , Gu Jane , Gao Hui , Williams Juliet A. , Stuart Darrin D. , Meyer Matthew J.
Published: April 2023

Gene expression analysis of pre- and on-treatment melanoma PDXs
Supplementary Figures S1-S11; Supplementary Table S1; and Supplementary Movie Legends from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin
Authors: Shukla Samriddhi , Milewski David , Pradhan Arun , Rama Nihar , Rice Kathryn , Le Tien , Flick Matthew J. , Vaz Sara , Zhao Xueheng , Setchell Kenneth D. , Logarinho Elsa , Kalinichenko Vladimir V. , Kalin Tanya V.
Published: April 2023

Supplementary Figure S1 shows that RCM-1 inhibits cell proliferation and increases the mitotic and cell cycle duration in cancer cells. Supplementary Figure S2 shows that RCM-1 treatment reduces mitotic index. Supplementary Figure S3 shows RCM-1 inhibits FOXM1 expression and nuclear localization in Rd76-9, B16-F10, MyC-CaP and KPC-2 cells. Supplementary Figure S4 shows RCM-1 inhibits FOXM-1 expression and nuclear localization in A549 and 4T1 cells. Supplementary Figure S5 shows that RCM-1 decreases clonogenicity and migration of tumor cells. Supplementary Figure S6 shows that RCM-1 inhibits FOXM1 and β-catenin mRNA and protein levels in tumor cells. Supplementary Figure S7 shows that RCM-1 inhibits FOXM1 and β-catenin in tumor cells. Supplementary Figure S8 shows that RCM-1 reduces growth of B16-F10 melanoma tumors. Supplementary Figure S9 shows RCM-1 reduces H2122 and 4T1 tumor growth. Supplementary Figure S10 shows that RCM-1 has optimal serum bioavailability. Supplementary Figure S11 shows that RCM-1 treatment does not alter body weight or liver enzyme profiles in mice. Supplementary Table T1 shows RCM-1 concentrations in mouse serum at different time intervals.
Supplemental Movie 6 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin
Authors: Shukla Samriddhi , Milewski David , Pradhan Arun , Rama Nihar , Rice Kathryn , Le Tien , Flick Matthew J. , Vaz Sara , Zhao Xueheng , Setchell Kenneth D. , Logarinho Elsa , Kalinichenko Vladimir V. , Kalin Tanya V.
Published: April 2023

Supplemental movie 6 shows live imaging to measure the cell cycle and mitotic duration in RCM-1-treated MyC-CaP cells.
Supplemental Movie 3 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin
Authors: Shukla Samriddhi , Milewski David , Pradhan Arun , Rama Nihar , Rice Kathryn , Le Tien , Flick Matthew J. , Vaz Sara , Zhao Xueheng , Setchell Kenneth D. , Logarinho Elsa , Kalinichenko Vladimir V. , Kalin Tanya V.
Published: April 2023

Supplemental movie 3 shows live imaging to measure the cell cycle and mitotic duration in Vehicle-treated B16-F10 cells.
Supplementary Figure 3 NP-12 increased the levels of IFN-γ in the Tetanus toxoid recall assay from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Authors: Sasikumar Pottayil G. , Ramachandra Raghuveer K. , Adurthi Srinivas , Dhudashiya Amit A. , Vadlamani Sureshkumar , Vemula Koteswararao , Vunnum Sriharibabu , Satyam Leena K. , Samiulla Dodderi S. , Subbarao Krishnaprasad , Nair Rashmi , Shrimali Rajeev , Gowda Nagaraj , Ramachandra Murali
Published: April 2023

Supplementary Figure 3 NP-12 increased the levels of IFN-γ in the Tetanus toxoid recall assay
Figure S3 from Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression
Authors: Hafeez Bilal Bin , Ganju Aditya , Sikander Mohammed , Kashyap Vivek K. , Hafeez Zubair Bin , Chauhan Neeraj , Malik Shabnam , Massey Andrew E. , Tripathi Manish K. , Halaweish Fathi T. , Zafar Nadeem , Singh Man M. , Yallapu Murali M. , Chauhan Subhash C. , Jaggi Meena
Published: April 2023

Effect of ORM on cell cycle analysis and β-catenin localization. A. Histogram (i) and table (ii) represent the cell cycle distribution in DU145 cells. B. Confocal images of β-catenin, DAPI and merged images of control (i) and ORM treated (ii) PC3 cells.
Supplementary Tables S1-S4 from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
Authors: Stewart Adam , Coker Elizabeth A. , Pölsterl Sebastian , Georgiou Alexandros , Minchom Anna R. , Carreira Suzanne , Cunningham David , O'Brien Mary ER. , Raynaud Florence I. , de Bono Johann S. , Al-Lazikani Bissan , Banerji Udai
Published: April 2023

Table S1: KRAS mutations in colorectal, lung and pancreatic cell lines. Table S2: Assay variability. Table S3: Significant changes in phosphoproteins seen in more than 50% of cell lines. Table S4: The GI50 concentrations of the two pan-PI3K inhibitors pictilisib and buparlisib used in validation experiments in Figure 4B.
Supplementary Figures S1-S3 from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
Authors: Stewart Adam , Coker Elizabeth A. , Pölsterl Sebastian , Georgiou Alexandros , Minchom Anna R. , Carreira Suzanne , Cunningham David , O'Brien Mary ER. , Raynaud Florence I. , de Bono Johann S. , Al-Lazikani Bissan , Banerji Udai
Published: April 2023

Figure S1: Hierarchically clustered heat map of mutations in the cell line panel. Figure S2: Heat map of median-centered CCLE cell line basal mRNA. Figure S3: Changes in pAKTSer473 quantified by ELISA.
Supplementary Figure S2 from Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers
Authors: Arora Arvind , Parvathaneni Swetha , Aleskandarany Mohammed A. , Agarwal Devika , Ali Reem , Abdel-Fatah Tarek , Green Andrew R. , Ball Graham R. , Rakha Emad A. , Ellis Ian O. , Sharma Sudha , Madhusudan Srinivasan
Published: April 2023

RECQL1 depletion and doxorubicin sensitivity in MCF-7 cells
Supplementary Methods; Supplementary Tables S1, S3; and Supplementary Figures S1-S2 from Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia
Authors: Papaioannou Dimitrios , Nicolet Deedra , Ozer Hatice G. , Mrózek Krzysztof , Volinia Stefano , Fadda Paolo , Carroll Andrew J. , Kohlschmidt Jessica , Kolitz Jonathan E. , Wang Eunice S. , Stone Richard M. , Byrd John C. , Garzon Ramiro , Bloomfield Clara D.
Published: April 2023

Supplementary Data, which contains text, tables and figures supportive of the results reported in the main manuscript. Text includes details about clinical trials protocols, RNA extraction techniques and statistical analyses. Tables include a list of prognostic long non-coding RNAs that are measured by the custom-designed nCounter assay and a list of mRNA transcripts that significantly associate with unfavorable lncRNA scores. Figures include scatterplots depicting the correlation of nCounter results in repeated measurements of samples of patients.
Supplementary figure 1 from TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Authors: Rodríguez-Ruiz María E. , Rodríguez Inmaculada , Mayorga Lina , Labiano Tania , Barbes Benigno , Etxeberria Iñaki , Ponz-Sarvise Mariano , Azpilikueta Arantza , Bolaños Elixabet , Sanmamed Miguel F. , Berraondo Pedro , Calvo Felipe A. , Barcelos-Hoff Mary Helen , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Assessment of spontaneous lung metastases of 4T1 tumors in the indicated treatment groups corresponding to mice treated as in figure 2A. Metastases were detected and quantitated -number of lesions in the surface of the lung counted upon inspection under a magnification lens (left) and by real time RT-PCR for tumor specific gp70 RNA (right)-.
Figure S2 from Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma
Authors: Xie Xiaoling , Chen Yiran , Hu Yuxing , He Yanjie , Zhang Honghao , Li Yuhua
Published: April 2023

The frequencies of T cell markers (CD28, CD40L, OX40 and 41BB) displayed on Eps8101-2L and Eps8cocktail treatment showed no significant difference. N. S, not significant. All data represent the mean {plus minus} SD (n = 3).
Supplemental Figure 4 from CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Authors: Xiang Jingyu , Hurchla Michelle A. , Fontana Francesca , Su Xinming , Amend Sarah R. , Esser Alison K. , Douglas Garry J. , Mudalagiriyappa Chidananda , Luker Kathryn E. , Pluard Timothy , Ademuyiwa Foluso O. , Romagnoli Barbara , Tuffin Gérald , Chevalier Eric , Luker Gary D. , Bauer Michael , Zimmermann Johann , Aft Rebecca L. , Dembowsky Klaus , Weilbaecher Katherine N.
Published: April 2023

Supplemental Figure 4. MDA-MB-231 primary tumor weight and liver metastases data.
Figure S5 from Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Authors: Chen Li-Hsien , Sun Yuan-Ting , Chen Yih-Fung , Lee Mei-Yi , Chang Lian-Yun , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

The neuroprotective effects of 5-HD in mouse model
Figure S2 from Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to Radiotherapy
Authors: Zernickel Erika , Sak Ali , Riaz Assad , Klein Diana , Groneberg Michael , Stuschke Martin
Published: April 2023

BRM expression of A549 (BRG1-) cells at day 0 (48 h after transfection), 3, 5 and 8 with and without irradiation of 15 Gy
Supplementary Tables S1-S8 from 17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells
Authors: Dai Sheng , Yang Shu , Hu Xin , Sun Wei , Tawa Gregory , Zhu Wenge , Schimmer Aaron D. , He Chao , Fang Bingliang , Zhu Hongbo , Zheng Wei
Published: April 2023

Supplementary Table S1. Summary of the antibodies used in experiments; Supplementary Table S2. List of compounds confirmed in the high throughput screening with DLD1-R cells; Supplementary Table S3. BECN1 knockdown re-sensitize DLD1-R cells to TRAIL; Supplementary Table S4. IC50 of TRAIL treatment in each cell line; Supplementary Table S5. 17-HW re-sensitizes multiple colon cancer cell lines to TRAIL; Supplementary Table S6. BECN1 knockdown re-sensitize multiple colon cancer cell lines to TRAIL; Supplementary Table S7. Patient demographics and baseline characteristics; Supplementary Table S8. Clinicopathological factors and their relationship to the expression of beclin1 and caspase-8
Supplementary Figures S1-S4 from 17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells
Authors: Dai Sheng , Yang Shu , Hu Xin , Sun Wei , Tawa Gregory , Zhu Wenge , Schimmer Aaron D. , He Chao , Fang Bingliang , Zhu Hongbo , Zheng Wei
Published: April 2023

Supplementary Figure S1. 17-hydroxy wortmannin (17-HW) overcomes TRAIL resistance in DLD1-R cells; Supplementary Figure S2. Increased BECN1 lead to CASP8 degradation in TRAIL-resistant cells; Supplementary Figure S3. TRAIL response is restored by the shBECN1 knockdown; Supplementary Figure S4. Controls for the effect of 17-HW in other colon cancer cell lines
Supplementary Figure S3 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Authors: Stremitzer Stefan , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Matsusaka Satoshi , Parekh Anish , Okazaki Satoshi , Hanna Diana , Astrow Stephanie H. , Moran Miriana , Hernandez Jose , Stephens Craig , Scherer Stefan J. , Stift Judith , Wrba Friedrich , Gruenberger Thomas , Lenz Heinz-Josef
Published: April 2023

Kaplan Meier curves for HIF1A mRNA levels in CLM for RFS (complete response, CR; not reached, NR)
Supplementary figure s2 from Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
Authors: Meerang Mayura , Bérard Karima , Felley-Bosco Emanuela , Lauk Olivia , Vrugt Bart , Boss Andreas , Kenkel David , Broggini-Tenzer Angela , Stahel Rolf A. , Arni Stephan , Weder Walter , Opitz Isabelle
Published: April 2023

Primary cells isolated from rat tumor did not response to SAG and vismodegib treatment
Supplemental Figure S5 from Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase Signalosome
Authors: Liu Miao , Feng Li-Xing , Sun Peng , Liu Wang , Mi Tian , Lei Min , Wu Wanying , Jiang Baohong , Yang Min , Hu Lihong , Guo De-An , Liu Xuan
Published: April 2023

Results of Western blotting assay of PARP and caspase-3 in wild type, negative control and APOE knockdown cells treated with BF (50 nM) for 24 h. Representative results of three independent experiments.
Supplemental Figure S1 from Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase Signalosome
Authors: Liu Miao , Feng Li-Xing , Sun Peng , Liu Wang , Mi Tian , Lei Min , Wu Wanying , Jiang Baohong , Yang Min , Hu Lihong , Guo De-An , Liu Xuan
Published: April 2023

Chemical structures of the cardiac steroids.
Supplemental Figure 6 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
Authors: Giulino-Roth Lisa , van Besien Herman J. , Dalton Tanner , Totonchy Jennifer E. , Rodina Anna , Taldone Tony , Bolaender Alexander , Erdjument-Bromage Hediye , Sadek Jouliana , Chadburn Amy , Barth Matthew J. , Dela Cruz Filemon S. , Rainey Allison , Kung Andrew L. , Chiosis Gabriela , Cesarman Ethel
Published: April 2023

BL tumors undergo growth suppression without apoptosis upon treatment with PU-H71 in-vivo.
Supplemental Figure 4 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
Authors: Giulino-Roth Lisa , van Besien Herman J. , Dalton Tanner , Totonchy Jennifer E. , Rodina Anna , Taldone Tony , Bolaender Alexander , Erdjument-Bromage Hediye , Sadek Jouliana , Chadburn Amy , Barth Matthew J. , Dela Cruz Filemon S. , Rainey Allison , Kung Andrew L. , Chiosis Gabriela , Cesarman Ethel
Published: April 2023

PU-H71 suppresses tumor growth in a Ramos xenograft Model.
Table S5 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Authors: Santos Cristina , Azuara Daniel , Garcia-Carbonero Rocio , Alfonso Pilar Garcia , Carrato Alfredo , Elez Mª Elena , Gomez Auxiliadora , Losa Ferran , Montagut Clara , Massuti Bartomeu , Navarro Valenti , Varela Mar , Lopez-Doriga Adriana , Moreno Victor , Valladares Manuel , Manzano Jose Luis , Vieitez Jose Maria , Aranda Enrique , Sanjuan Xavier , Tabernero Josep , Capella Gabriel , Salazar Ramon
Published: April 2023

Overall Response Rate (ORR) in the anti-EGFR group (N = 223)